Sandoz Wins Expanded U.S. FDA Label for Enzeevu Retinal Biosimilar

Sandoz Group Ltd ( (CH:SDZ) ) has shared an announcement.

Sandoz has secured U.S. FDA approval to expand the label of its aflibercept biosimilar Enzeevu to cover all major retinal indications, including macular edema following retinal vein occlusion, diabetic retinopathy and diabetic macular edema, in addition to its existing nod for neovascular age-related macular degeneration. With more than 30 million Americans affected by retinal diseases, the broader label and planned U.S. launch in the fourth quarter of 2026 bolster Sandoz’s ophthalmology franchise alongside Cimerli and Afqlir, reinforcing its push to capture a larger share of the fast-growing global biosimilar market and potentially lowering treatment costs for patients and payers.

The most recent analyst rating on (CH:SDZ) stock is a Buy with a CHF75.00 price target. To see the full list of analyst forecasts on Sandoz Group Ltd stock, see the CH:SDZ Stock Forecast page.

More about Sandoz Group Ltd

Sandoz Group AG is a Switzerland-based global leader in affordable medicines, specializing in generics and biosimilars that span conditions from common illnesses to cancer. With a portfolio of about 1,300 products and 13 marketed biosimilars, the company focuses on expanding access to biologic therapies worldwide, supported by more than 20,000 employees and over 900 million patient treatments annually.

Average Trading Volume: 739,873

Technical Sentiment Signal: Buy

Current Market Cap: CHF28.88B

See more insights into SDZ stock on TipRanks’ Stock Analysis page.